Administration, wherein the participation of the FDA is contingent on resolution of any apparent conflict of interest issues, includes the following:

1. Determine the stability, half-life, and distribution of the Tat peptides upon delivery into cells.
2. Determine the mechanism of the Tat peptide inhibition.
3. Determine the inhibitory effect of peptides on human ''primary'' T-lymphocytic and monocytic cells infected with various HIV–1 clades (subtypes A, G, O, M).
4. Determine the inhibitory effect of peptide derivatives on Kaposi's sarcoma primary cells.
5. Determine the effective dose of Tat peptide analogs in combination with other anti-retroviral drugs.
6. Conduct in vivo testing of appropriate compounds and/or peptide analogs.
7. Evaluate in vivo test results.
8. Prepare manuscripts for publication.

The role of the collaborator, includes the following:

1. Synthesize soluble organic compounds using peptide mimetics to mimic the inhibitory activity of the soluble analogs.
2. Determine the mechanism of the Tat peptide inhibition.
3. Establish a suitable non-invasive peptide delivery system for the preclinical and animal model studies.
4. Determine the effective dose of Tat peptide analogs in combination with other anti-retroviral drugs.
5. Determine the stability, half-life, and distribution of the Tat peptides upon delivery into cells.
6. Conduct in vivo testing of appropriate compounds and/or peptide analogs.
7. Evaluate in vivo test results.
8. Develop vehicle for delivery of compounds to patients.
9. Conduct pre-clinical and clinical trials of appropriate candidate compounds and/or peptide analogs.
10. Prepare manuscripts for publication.

Criteria for choosing the collaborator include its demonstrated experience and commitment to the following:

1. The aggressiveness of the development plan, including the appropriateness of milestones and deadlines for preclinical and clinical development.
2. Scientific expertise in and demonstrated commitment to the development of drug delivery systems.
3. Experience in preclinical and clinical drug development.
4. Experience and ability to produce, package, market and distribute pharmaceutical products.
5. Experience in the monitoring, evaluation and interpretation of the data from investigational agent clinical studies under an IND.
6. A willingness to cooperate with the NCI and FDA in the collection, evaluation, publication and maintaining of data from pre-clinical studies and clinical trials regarding the subject compounds.
7. Provision of defined financial and personnel support for the CRADA to be mutually agreed upon.
8. An agreement to be bound by the DHHS rules involving human and animal subjects.
9. Scientific expertise in and demonstrated commitment to the treatment of HIV infection and related disorders.
10. Provisions for equitable distribution of patent rights to any CRADA inventions. Generally the rights of ownership are retained by the organization which is the employer of the inventor, with (1) an irrevocable, nonexclusive, royalty-free license to the Government and (2) an option for the collaborator to elect an exclusive or nonexclusive license to Government owned rights under terms that comply with the appropriate licensing statutes and regulations.

Dated: February 7, 1997.

Thomas D. Mays,

Director, Office of Technology Development, OD, NCI.

[FR Doc. 97–4742 Filed 2–25–97; 8:45 am]

BILLING CODE 4140–01–M

National Institutes of Health (NIH)

Notice of a Meeting of the Office of AIDS Research Advisory Council

Pursuant to Public Law 92–463, notice is hereby given of the Fourth meeting of the Office of AIDS Research Advisory Council (OARAC) on Friday, March 14, 1997, at the National Institutes of Health, 9000 Rockville Pike, Building 31, C Wing, Sixth Floor, Conference Room 6. The meeting will be open to the public from 8:30 am to 3:30 pm.

The Office of AIDS Research is responsible for the planning, coordination, and evaluation of the NIH AIDS research program. The OARAC was established to advise the Director of the OAR regarding these activities.

The agenda of the open meeting will include: The FY 1998 budget request for NIH AIDS research; presentation of the NIH Implementation Plan in response to the Report of the NIH AIDS Research Program Evaluation Task Force; an update on the NIH Panel to Define Principles of Therapy of HIV Infection; an update on the Prevention Science Working Group; and presentations regarding the new initiatives in AIDS vaccine research.

In accordance with the provisions set forth in section 552b(c)(9)(B), Title 5 U.S.C. and section 10(d) of the Federal Advisory Committee Act, Public Law 92–463, the meeting will be closed to the public from 3:45 p.m. until adjournment for discussions of which the premature disclosure could impede implementation of recommendations.

Copies of the meeting agenda and the roster of council members will be furnished upon request by Jeannette R. De Lawter, Program Analyst, Office of AIDS Research, National Institutes of Health, Building 31, Room 4B54, 9000 Rockville Pike, Bethesda, MD 20892, Phone (301) 402–3357, Fax (301) 402–3360. Any individual who requires special assistance, such as sign language interpretation or other reasonable accommodations, should contact Mrs. De Lawter no later than March 6.

Dated: February 21, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–4735 Filed 2–25–97; 8:45 am]

BILLING CODE 4140–01–M

National Cancer Institute; Notice of Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2) notice is hereby given of advisory committee meetings of the National Cancer Institute.

The meetings will be open to the public as indicated below, with attendance by the public limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Ms. Cynthia Morgan, Committee Management Specialist, at (301) 496–5708 in advance of the meetings.

A portion of the meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4), 552b(c)(6), and 552(c)(9)(B), Title 5, U.S.C. and section 10(d) of Public Law 92–463, for the review, discussion and evaluation of individual programs and for discussion of issues pertaining to programmatic areas and/or NCI personnel. These discussions could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning the individuals associated with the programs, including consideration of personnel